Edimer Initiates Phase 2 Trial of EDI200 in XLHED-Affected Male Newborns Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia , today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company’s novel, proprietary, recombinant protein.
Oct. 8, 2013 - Business Wire via Yahoo! Finance